1 min readNew Antibody-Based Zika Virus Therapeutic Shows Promise in Monkey Study
Bethesda, MD —Using blood samples from an individual previously infected with Zika virus, scientists funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed an antibody-based Zika virus therapeutic that protected monkeys from infection.
Because monoclonal antibodies are generally safe, they believe that this antibody cocktail might be appropriate for uninfected pregnant women; because the antibodies will likely cross the placenta, the researchers hope that administration during pregnancy may protect both the pregnant woman and the foetus from Zika virus. The investigators are hoping to test this concept by pursuing studies in people.
The scientists isolated immune cells from the patient’s blood and used them to make 91 monoclonal antibodies — immune system fighters designed to bind to a specific part of an invading virus or bacterium to stop the infection. They identified three antibodies that bound to Zika virus surface proteins, and each neutralized the virus. The researchers then administered a combination of these antibodies to rhesus macaques and exposed the animals to Zika virus one day later. During the 21-day study, all four monkeys who received the antibody cocktail showed no virus replication.
Article adapted from a NIH/National Institute of Allergy and Infectious Diseases news release.
Publication: Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. D Magnani, et al. Science Translational Medicine (2017): Click here to view.